Phase 2
Completed N=33
A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis
Source: ClinicalTrials.gov NCT06176768 ↗Enrolled (actual)
33
Serious AEs
3.0%
Results posted
Oct 2025
Primary outcomePrimary: Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) — 18.8; 5.9 percentage of participants — p=0.316
Summary
The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) |
18.8; 5.9 | 0.316 |
| SECONDARY Change From Baseline in Percent Body Surface Area (BSA) |
-7.26; -0.48 | 0.175 |
| SECONDARY Change From Baseline in Dermatology Life Quality Index (DLQI) |
-6.71; -4.35 | 0.311 |
| SECONDARY Pharmacokinetics (PK): Observed Trough Plasma Concentration of LY3972406 |
158 | — |
Eligibility Criteria
Inclusion Criteria
- Have moderate-to-severe chronic plaque psoriasis for at least 6 months prior to baseline
- Have venous access sufficient to allow for blood sampling
- Are able to swallow oral medication
Exclusion Criteria
- Have any other skin conditions, excluding plaque psoriasis
- Have a current or recent acute, active infection
- Have manifestations of other autoimmune diseases, such as systemic lupus erythematosus.
- Are lactating or breastfeeding women
Data sourced from ClinicalTrials.gov (NCT06176768). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.